November 17, 2016 – Triphase Accelerator Announces that Celgene Corporation has acquired the company’s assets related to its proteasome inhibitor, marizomib, which is in development for glioblastoma and relapsed and/or refractory multiple myeloma.
November 2, 2016 – FACIT-created Turnstone Biologics raises USD $41M, one of the largest Series B rounds for a Canadian biotech, attracting blue-chip healthcare investors to accelerate commercialization of proprietary oncolytic viral immunotherapies.
Read More from FACIT Start-up Turnstone Biologics Closes USD $41M Financing
October 4, 2016 – Triphase will obtain worldwide rights to further develop Catalent’s proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent’s wholly owned subsidiary, Redwood Bioscience, Inc., using its SMARTag™ technology platform.
June 23, 2016 – The creation of Propellon to manage the development and commercialization of a portfolio of first-in-class epigenetic therapeutics, WDR5 inhibitors, enables important development activities including attracting private sector investment and industry partnerships.
Read More from Propellon Therapeutics to Accelerate WDR5 Inhibitor Development for Cancers
May 26, 2016 – The transaction combines Privacy Analytics’ leading edge expertise in health data anonymization and de-identification with IMS Health’s broad range of healthcare information, technology and services solutions.
January 28, 2016 – Trillium Therapeutics has acquired all of the outstanding shares of privately-held Fluorinov Pharma, a FACIT portfolio company.
Read More from Trillium Therapeutics Acquires Fluorinov Pharma
December 16, 2015 – FACIT’s investment will support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer.
December 8, 2015 – FACIT acquires exclusive rights to a portfolio of first-in-class WDR5 inhibitors for the treatment of mixed lineage leukemia.
Read More from FACIT Gains Rights to WDR5 Inhibitors for MLL Leukemia
November 19, 2015 – Triphase is evaluating marizomib in combination with bevacizumab in patients with recurrent glioblastoma.
October 28, 2015 – Versant Ventures-led investment accelerates development, broadens oncolytic viral immunotherapy potential.